Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

20.51B

Market cap20.51B

Price-Earnings ratio

12.53

Price-Earnings ratio12.53

Dividend yield

—

Dividend yield—

Average volume

2.02M

Average volume2.02M

High today

$140.80

High today$140.80

Low today

$138.63

Low today$138.63

Open price

$139.44

Open price$139.44

Volume

271.62K

Volume271.62K

52 Week high

$238.00

52 Week high$238.00

52 Week low

$128.51

52 Week low$128.51

BIIB News

Seeking Alpha 3d

Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting th...

TipRanks 3d

Biogen announces initiation of dosing in TRANSCEND

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investi...

Analyst ratings

51%

of 37 ratings

Buy

48.6%

Hold

51.4%

Sell